FDA approves biosimilar for adults with non-Hodgkin’s lymphoma

Author(s):

biosimilar adults non-hodgkins lymphoma

On Nov. 28, the FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

Read more via U.S. Food & Drug Administration.

LEAVE A REPLY

Please enter your comment!
Please enter your name here